NCT03505190View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

July 5, 2019

Study Completion Date

July 5, 2019

Conditions
Healthy Participants
Interventions
DRUG

RO7062931

RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.

DRUG

Placebo

Matching placebo will be administered subcutaneously (SC).

Trial Locations (2)

Unknown

Queen Mary Hospital, Hong Kong

Prince of Wales Hospital, Shatin, New Territories

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03505190 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers. | Biotech Hunter | Biotech Hunter